- CFO Spotlights
- Profiles
- Gianluca Fuggetta
Profile
Gianluca Fuggetta
Senior Vice President Finance (Principal Financial Officer and Principal Accounting Officer), Gain Therapeutics, Inc.
Former. First published here October 28, 2026; built from records as of October 28, 2026.
Gain Therapeutics, Inc. named Gene Mack to succeed Gianluca Fuggetta on an interim basis, effective October 1, 2026.2
Seats
The seat in the record
| Company | Title as filed | Standing |
|---|---|---|
| Gain Therapeutics, Inc. (GANX) Pharmaceutical Preparations | Senior Vice President Finance (Principal Financial Officer and Principal Accounting Officer) | Former |
Company names link to the company's page in the record at CFO Tribune, which holds the seat history.
The record
Filing by filing, latest first
- October 1, 2026effective
Gain Therapeutics, Inc. named Gene Mack to succeed Gianluca Fuggetta on an interim basis, effective October 1, 2026. Profile of Gene Mack.
[2] Filing by Gain Therapeutics, Inc., filed with the SEC on September 28, 2026. Read the filing. The record at CFO Tribune.
- March 26, 202610-K filed
Gianluca Fuggetta signed the annual report of Gain Therapeutics, Inc. on Form 10-K as Senior Vice President Finance (Principal Financial Officer and Principal Accounting Officer), filed March 26, 2026.
/s/ Gianluca Fuggetta Gianluca Fuggetta Senior Vice President Finance ( Principal Financial Officer and Principal Accounting Officer )
[1] Annual report on Form 10-K by Gain Therapeutics, Inc., filed with the SEC on March 26, 2026. Read the filing. The record at CFO Tribune.
Sources
Sources
- Annual report on Form 10-K, Gain Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed March 26, 2026. sec.gov; record.
- Current report filed with the SEC, Gain Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed September 28, 2026. sec.gov; record.
Corrections and removal
If a line here is wrong, or Gianluca Fuggetta wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.